{
    "filename": "0001213900-25-091474_primary_doc.xml",
    "path": "filings_cache\\0001213900-25-091474_primary_doc.xml",
    "date": "2025-09-25",
    "form": "SCHEDULE 13D",
    "file_type": "SCHEDULE 13D",
    "original_filename": "primary_doc.xml",
    "accession": "0001213900-25-091474",
    "cik": "0001691082",
    "label": "Signal activist investment or strategic involvement",
    "summary": "Pontifax Management 4 G.P. (2015) Ltd., Pontifax VI G.P. L.P., Ran Nussbaum, and Tomer Kariv (the \"Reporting Persons\") have filed a Schedule 13D for LB Pharmaceuticals Inc. The Reporting Persons collectively beneficially own 1,411,681 shares of Common Stock, representing 6.3% of the outstanding class. These shares were acquired through the conversion of Series C Preferred Stock and an additional purchase of 990,000 shares in the Issuer's initial public offering (IPO) at $15.00 per share, both on September 12, 2025. The securities are held for investment purposes, and Ran Nussbaum, a Managing Partner of Pontifax Management, serves on LB Pharmaceuticals Inc.'s Board of Directors.",
    "share %": null
}